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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.026Human papillomavirus is the main cause of cervical cancer, yet other nonviral cofactors are also required
for the disease. The uterine cervix is a hormone-responsive tissue, and female hormones have been
implicated in cervical carcinogenesis. A transgenic mouse model expressing human papillomavirus
oncogenes E6 and/or E7 has proven useful to study a mechanism of hormone actions in the context of
this common malignancy. Estrogen and estrogen receptor a are required for the development of cervical
cancer in this mouse model. Estrogen receptor a is known to up-regulate expression of the progesterone
receptor, which, on activation by its ligands, either promotes or inhibits carcinogenesis, depending on
the tissue context. Here, we report that progesterone receptor inhibits cervical and vaginal epithelial
cell proliferation in a ligand-dependent manner. We also report that synthetic progestin medrox-
yprogesterone acetate promotes regression of cancers and precancerous lesions in the female lower
reproductive tracts (ie, cervix and vagina) in the human papillomavirus transgenic mouse model. Our
results provide the ﬁrst experimental evidence that supports the hypothesis that progesterone signaling
is inhibitory for cervical carcinogenesis in vivo. (Am J Pathol 2013, 183: 1679e1687; http://dx.doi.org/
10.1016/j.ajpath.2013.07.026)Supported by University of Houston Small Grant Program and Univer-
sity of Houston New Faculty Award (S.-H.C.); NIH grants CA141583
(P.F.L.), R01 CA-77530 (J.P.L.), and U54 HD-0077495 (F.J.D.); and the
Texas Emerging Technology Fund (Center for Nuclear Receptors and Cell
Signaling).High-risk human papillomavirus (HPV) is a small DNA tumor
virus that infects the mucosal squamous epithelium and causes
variousmalignant diseases in humans, including cancers of the
cervix and oral cavity.1,2 HPV-associated cancers are mainly
caused by the oncogenic activities of E6 and E7, which interact
with key cellular proteins that regulate various cellular
processes, including, but not limited to, cell cycle and
apoptosis.1 Most notably, E6 promotes proteasome-mediated
degradation of p53 and E7 inactivates pRb. Among more
than a dozen high-risk HPV types, HPV16 is most commonly
associated with cancers.1 Transgenic mice expressing HPV16
E6 (K14E6 mice) or E7 (K14E7 mice) have been valuable to
study a molecular mechanism of an individual viral oncopro-
tein in promoting cancers in vivo.3,4 The expression of E6 and
E7 in these mice is under the transcriptional control of human
keratin 14 (K14) promoter, which drives transgene expression
in the stratiﬁed squamous epithelia, the cell type normally
infected by HPV in humans.5,6
Cervical cancer is the third most frequent malignancy and
the fourth leading cause of cancer death inwomenworldwide.7stigative Pathology.
.Most of the cancer is associated with high-risk HPVs. Papa-
nicolaou smear and HPV vaccines are effective in preventing
the disease.8 These preventive methods, however, are not
readily available to women in developing countries where
cervical cancer ismost prevalent. The traditional treatments for
the cancer (ie, surgery, chemotherapy, and radiation) have
limited efﬁcacy in treating late-stage or recurrent diseases.9
Better understanding of cervical cancer pathogenesis will
help to develop an effective therapy for the late-stage diseases.
Despite the potent tumorigenic activities of E6 and E7,
HPV-positive dysplastic cervical lesions (ie, cervical intra-
epithelial neoplasia; CIN) often regress spontaneously, and
only a minor fraction of HPV-infected women succumb to
cervical cancer.10 These observations suggest that HPV
alone is not sufﬁcient and that other cofactors are involved
Yoo et alin cervical carcinogenesis. Studies that use the HPV trans-
genic mouse models have identiﬁed estrogen (estradiol, E2)
as a cofactor for HPV-associated cervical cancer.11,12 On
chronic treatment with E2, the HPV transgenic mice but not
nontransgenic control mice develop cervical cancer. This is
consistent with an epidemiological ﬁnding that the long-
term use of oral contraceptives increases the risk of
cervical cancer in HPV-infected women.13 Using the same
mouse model, we have further found that estrogen receptor
a (ERa) is necessary for the genesis and continued growth
of the cancer14,15 and that ERa expressed in stromal cells is
required for the progression of the disease.16
Progesterone receptor (PR) is activated by its ligand
progesterone (P4), which is another major female hormone.
PR can be also activated by synthetic progestins such as
medroxyprogesterone acetate (MPA) that is commonly used
as an injectable contraceptive. PR plays a crucial role in
normal physiology and pathophysiology in the hormone-
responsive tissues such as the breast and the uterus.17,18
Unlike the universal mitogenic function of ERa in those
tissues, PR promotes breast cancer, whereas it inhibits
endometrial cancer. The PR gene is also implicated as
a tumor suppressor in ovarian cancer.19 The cervix is a P4-
responsive tissue.20 Epidemiological studies that looked at
the association between the use of PR agonist MPA and the
risk of cervical diseases have yielded conﬂicting results.
Several caseecontrol studies have shown that MPA is not
a risk factor for the disease.21e23 Other studies have sug-
gested that the use ofMPA increases the risk of the neoplastic
disease in the cervix.24e26 It has also been shown that MPA
use is inversely associated with the cervical disease in HPV-
positive women.27 Therefore, a role of the P4 signaling in
human cervical cancer remains elusive. In the present study,
we evaluated the effect of MPA or PR ablation on cancers of
the cervix with the use of the HPV transgenic mice. Our
results support the hypothesis that P4 signaling inhibits
carcinogenesis in the female lower reproductive tract.
Materials and Methods
Mice
K14E6, K14E7, and PRLacZ/LacZ (referred to as PR/
herein) mice were described previously.5,6,28 Experimental
mice were generated by crossing K14E7/PRþ/ and non-
transgenic (NTG)/PRþ/, which were obtained by mating
K14E7 (FVB) with PRþ/ (C57BL/6  129Sv). Double
transgenic mice were generated by mating K14E7 males and
K14E6 females. Female progenies were genotyped by PCR.
Mice were intraperitoneally injected with 0.3 mL of 12.5
mg/mL bromo-deoxyuridine (BrdU) 1 hour before eutha-
nasia to measure cellular proliferation. All procedures were
performed according to an animal protocol approved by the
University of Houston Institutional Animal Care and Use
Committee and the University of Wisconsin Medical School
Institutional Animal Care and Use Committee.1680Hormone Treatments
Groups of female mice underwent ovariectomy at 6 to 8
weeks of age and were allowed to recover for 2 weeks. They
were then intraperitoneally injected with ethanol vehicle, 1
mg of E2 alone, or 1 mg of E2 plus 1 mg of P4 for 10 days.
For cancer studies, slow-release, 17b-estradiol tablets (0.05
mg for 60 days; Innovative Research of America, Sarasota,
FL) were inserted subcutaneously under the dorsal skin
every 2 months beginning at 4 to 6 weeks of age as previ-
ously described.11 Groups of mice were intraperitoneally
injected with 4.5 mg of MPA (SICOR Pharmaceuticals,
Irvine, CA) once a month.
Tissue Processing and Histological Analysis
Female mouse reproductive tracts were ﬁxed in 4% para-
formaldehyde and embedded in parafﬁn. Serial sections (5
mm thick) were made throughout cervices. Every 10th slide
was stained with H&E, and the worst stage of neoplastic
disease in each mouse was determined as described previ-
ously.12 Alcian Blue staining was performed according to
the manufacturer’s manual. Brieﬂy, parafﬁn sections were
deparafﬁnized, rehydrated, and then stained in 1% Alcian
Blue solution (Electron Microscopy Sciences, Hatﬁeld, PA)
for 30 minutes and rinsed in water. Nuclei were counter-
stained with 0.1% nuclear fast red (Electron Microscopy
Sciences) for 5 minutes.
Immunohistochemistry
Antibodies were purchased from Santa Cruz Biotechnology
[Santa Cruz, CA; PR (H190), ERa (MC20)], Calbiochem
(San Diego, CA; BrdU), NeoMarkers (Fremont, CA;
MCM7), and Rockland Immunochemicals (Gilbertsville, PA;
biotinylated anti-rabbit/mouse IgG). Immunohistochemical
staining for MCM7 and BrdU was performed as previously
described.3,12,14 For PR staining, sections were blocked in
10% goat serum diluted in PBS for 30 minutes. The sections
were then incubated with PR antibody (1:200 in blocking
buffer) at 4C overnight, washed in PBS, and incubated with
1:100 biotinylated goat anti-rabbit IgG for 30 minutes fol-
lowed by a 30-minute incubation with ABC complex (Vector
Laboratories, Burlington, CA) according to the manufac-
turer’s instructions. The immune complex was visualized by
an incubation in 3,30-diaminobenzidine (Sigma-Aldrich, St.
Louis, MO) dissolved in 0.5 mg/mL PBS.
Statistical Analysis
One-sided Fisher exact test and Wilcoxon rank sum test
were performed with MSTAT software version 5.5 (http://
www.mcardle.wisc.edu/mstat, last accessed April 30,
2013). Fisher exact test was used for cancer incidence, and
Wilcoxon rank sum test was used for disease severity and
proliferation indices.ajp.amjpathol.org - The American Journal of Pathology
PR Signaling in Cervical CancerResults
P4 Inhibits Epithelial Cell Proliferation in the Lower
Reproductive Tracts of Female Mice
The proliferation of epithelial cells in the mouse female lower
reproductive tracts (ie, cervix and vagina) depends on E2 and
ERa, and PR is one of its transcriptional targets.14,29 To
determine a role of PR in epithelial cell proliferation in those
tissues, we treated mice that have undergone ovariectomywith
vehicle, E2 alone, or E2 plus P4 for 10 days. Although the
cervical epithelia of vehicle-treated mice were hypoplastic
regardless of the PR status (Figure 1A), cervical epithelia of
E2-treated mice displayed physiological hyperplasia in both
PRþ/þ and PR/ mice (Figure 1A). Such hyperplasia was
absent in PRþ/þ but was maintained in PR/ mice when
treated with E2 plus P4 (Figure 1A). We observed similar
phenotypes in ovary-intact mice (data not shown). We also
analyzed cell proliferation by measuring BrdU incorpora-
tion, which is indicative of DNA synthesis (ie, cells in
S phase). Consistent with histological analyses, compared
with vehicle-treated mice, E2 signiﬁcantly increased
cervical epithelial cell proliferation in both PRþ/þ and
PR/ mice at the similar level (Figure 1, B and C). The
E2-induced epithelial cell proliferation was abrogated by P4
in PRþ/þ but not in PR/ cervices (Figure 1, B and C).
Similar results were obtained in the vaginal epithelium
(Figure 1D). These results indicate that the P4ePR signaling
axis inhibits E2-induced epithelial cell proliferation in the
female lower reproductive tracts.The American Journal of Pathology - ajp.amjpathol.orgMPA Promotes Regression of Cervical and Vaginal
Diseases in HPV Transgenic Mice
Antiproliferative effect of P4 on cervical and vaginal
epithelial cells prompted us to investigate if PR agonists are
effective in treating cancers in the lower reproductive tracts of
female mice. We ﬁrst evaluated PR status in cervical cancers
arising in our mouse model and found it was expressed in all
cervical cancers we evaluated (Supplemental Figure S1). We
chose to use depot-MPA that slowly releases PR agonist MPA
and induces hypoplasia in the vaginal epithelium of mice.30
We ﬁrst performed dosing experiments and determined that
4.5 mg of MPA induces hypoplasia in the cervical epithelia
for a month (Supplemental Figure S2).We then treated ovary-
intact K14E7 single transgenic mice with E2 for 6 months and
then with E2 plus PBS (vehicle group) or E2 plus MPA (MPA
group) for an additional 2 months. Six-month treatment with
E2 resulted in cervical cancer or CIN lesions in all mice
(Supplemental Table S1; control group) similar to previously
published results.16 The vehicle group treated with E2 for 8
months had more severe cervical diseases than did the control
group (P Z 0.012), which is consistent with previously
published results.16 Strikingly, none of the 14 mice in the
MPA group had cervical cancer or CIN lesions (Supplemental
Table S1). The cancer incidence was signiﬁcantly different
from the vehicle group (P Z 0.006). MPA showed similar
effect on vaginal diseases (Supplemental Table S1). We also
generated K14E6/K14E7 double transgenic mice and divided
them into three treatment groups (Figure 2A). All mice were
treated with E2 for 6 months, and the reproductive tracts wereFigure 1 Activated PR inhibits E2-induced
epithelial cell proliferation in the female lower
reproductive tracts. A: P4 inhibits E2-induced physi-
ological hyperplasia in the cervical epithelia in
a PR-dependent manner. Mice that underwent ovari-
ectomy were treated with Veh, E2, or E2 þ P4. Shown
are photomicrographs of representative H&E-stained
cervical sections. Black lines indicate the basement
membrane. B: E2-induced DNA synthesis is inhibited
by P4 in PR
þ/þ but not PR/ cervices. Cervical
sections described in A were stained for BrdU, and
nuclei were counterstained with hematoxylin. C:
Results shown in B were quantiﬁed. Five random
microscopic ﬁelds per mouse cervical tissue were
examined. Results are shown as means SEM (PR/
E2þ P4 group, nZ 4; the other groups, nZ 3; (same
number of mice were analyzed in A, B, and D). D: P4
inhibits E2-induced cell proliferation in the vaginal
epithelia. Vaginal tissue sections obtained from mice
described in A were stained for BrdU, quantiﬁed, and
presented as described in C. P Z 0.02 by Wilcoxon
rank sum test. Scale bars: 50 mm (A); 100 mm (B).
BrdU, bromo-deoxyuridine; E2, estrogen; P4, proges-
terone; PR, progesterone receptor; Veh, vehicle.
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Figure 2 MPA promotes muciniﬁcation and inhibits cell proliferation in the cervical epithelium. A: K14E6/K14E7 double transgenic mice were treated as
depicted. B: MPA promotes hypoplasia and muciniﬁcation of epithelial cells in the cervix. Representative photomicrographs of H&E-stained or Alcian Blue-
stained cervical sections are shown, and group size is indicated in A. Arrowheads point to muciniﬁed cells. Black lines delineate the basement membrane. C:
MPA promotes muciniﬁcation of cervical cancer. K14E6/K14E7 double transgenic mice were treated with E2 for 6 months and then with PBS vehicle or MPA for
2 weeks (nZ 3 per treatment). Cancers in each group were stained with Alcian Blue. Note that Alcian Blue staining is evident in MPA-treated cancer. (D) MPA
inhibits cervical epithelial cell proliferation. Cervical sections described in A and B were stained for BrdU, and nuclei were counterstained with hematoxylin.
Black lines delineate the basement membrane. E: Results shown in D were quantiﬁed. BrdU-positive cells were counted in basal and suprabasal layers. Results
are shown as means  SEM (nZ 3). PZ 0.02 by Wilcoxon rank sum test. Scale bars: 50 mm (BeD). BrdU, bromo-deoxyuridine; E2, estrogen; K14, keratin 14;
MPA, medroxyprogesterone acetate.
Yoo et alisolated from one group immediately after 6-month treatment
(control group). Another group was maintained for an addi-
tional 2 months with PBS vehicle treatment (vehicle group),
and the third group was treated withMPA for 2 months (MPA
group). Consistent with previously published results,15 allTable 1 Summary of Lower Reproductive Tract Diseases in K14E6/K14
Treatment
group
Group
size, No.
No disease, No. Dysplasia only, No.
Cervix (vagina) CIN1 (VIN1) CIN2 (VIN2)
Control 7 0 (0) 0 (1) 0 (2)
Vehicle 10 0 (0) 0 (2) 0 (2)
MPA 11 11 (10) 0 (0) 0 (0)
Mice were scored for the worst disease present in the cervix or, in parentheses,
lesion was given the following arbitrary score; no disease Z 0; CIN1 (VIN1) Z
CIN, cervical intraepithelial neoplasia; K14, keratin 14; MPA, medroxyprogeste
1682mice (7 of 7) in the positive control (ﬁrst) group developed
cervical cancer and dysplasia (Table 1), indicating that all
mice in the MPA group had the cancer as well as CIN at the
time of the ﬁrst MPA injection. Although the cancer was
retained in 9 of 10 mice (90%) that were maintained forE7 Mice
Cancer and dysplasia, No. Cancer incidence, %
CIN3 (VIN3) Cervix (vagina) Cervix (vagina)
0 (1) 7 (3) 100 (42.8)
1 (3) 9 (3) 90 (30)
0 (0) 0 (1) 0 (9.1)
the vagina. Note: for Wilcoxon rank sum test (see Statistical Analysis), each
1; CIN2 (VIN2) Z 2; CIN3 (VIN3) Z 3; cancer Z 4.
rone acetate; VIN, vaginal intraepithelial neoplasia.
ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Function of E7 and ERa is retained in MPA-treated mice. A:
Cervical sections fromK14E6/K14E7double transgenicmice treatedwith vehicle
or MPA were stained for MCM7 (n Z 3). Nuclei were counterstained with
hematoxylin. NTG cervical sections were used as control. B: Cervical sections
shown in A were stained for ERa or PR. Nuclei were counterstained with
hematoxylin. Representative photomicrographs of three tissues from each
treatment are shown. ERa, estrogen receptor a; K14, keratin 14; MPA,
medroxyprogesteroneacetate; NTG, non-transgenic; PR, progesterone receptor.
PR Signaling in Cervical Cancer2 months without MPA (vehicle group), none of the 11 mice
that were treated with MPA (MPA group) had cervical cancer
(Table 1). The difference in cervical cancer incidence between
vehicle and MPA group was highly signiﬁcant (P Z 3.4 
105). We also found that MPA-treated mice did not have
CIN lesions (Table 1). We observed a similar therapeutic
effect of MPA on neoplastic disease of the vagina (Table 1).
These results indicate that MPA promotes regression of
cervical/vaginal cancers as well as dysplastic lesions in the
HPV transgenic mouse model.MPA Induces Muciniﬁcation of Cervical Cancer Cells
and Inhibits Cervical Epithelial Cell Proliferation
Histological analyses of the female reproductive tracts
described in Table 1 found that the cervical epithelia inTable 2 State of Lower Reproductive Tract Diseases in PRþ/þ and PR
Genotypes
Group
size, No.
No disease, No. Dysplasia only, No.
Cervix (vagina) CIN1 (VIN1) CIN2 (VIN2)
NTG/PR/ 29 19 (27) 8 (1) 2 (1)
NTG/PRþ/þ 25 21 (25) 4 (0) 0 (0)
K14E7/PR/ 13 1 (5) 0 (5) 4 (1)
K14E7/PRþ/þ 24 0 (6) 2 (7) 10 (9)
Mice were scored histopathologically for the worst disease present in the cerv
CIN, cervical intraepithelial neoplasia; K14, keratin 14; NTG, non-transgenic; P
The American Journal of Pathology - ajp.amjpathol.orgMPA-treated mice were hypoplastic compared with those in
the vehicle control (Figure 2B). We also noted that cells at the
top layer of the cervical epithelia in the MPA-treated mice had
clear cytoplasm (Figure 2B). These cells were strongly stained
with Alcian Blue (Figure 2B), indicating muciniﬁcation of
epithelial cells. Muciniﬁcation was also evident in the vaginal
epithelia of MPA-treated mice (Supplemental Figure S3). To
determine whether MPA also promotes muciniﬁcation in
cervical cancer cells, a subset of K14E6/K14E7 mice treated
with E2 for 6 months was treated with MPA for 2 weeks.
Although the cervical cancers in vehicle-treated mice were
negative for Alcian Blue staining, those in MPA-treated mice
were strongly stained (Figure 2C). The epithelial cell prolif-
eration was signiﬁcantly reduced in both basal and suprabasal
layers in MPA-treated mice compared with the vehicle control
(Figure 2, D and E). These results suggest that MPA induces
terminal differentiation of cervical cancer cells and inhibits
their proliferation.
MPA Does Not Affect Expression of HPV Oncogenes and
ERa
K14 promoter drives expression of E6 and E7 in the transgenic
mice.5,6 E7 results in E2F activation by inactivating pRb and
thus up-regulates E2F target genes such as minichromosome
maintenance complex component 7 (MCM7).3 To address
whether MPA negatively affected K14 promoter in K14E6/
K14E7 double transgenic mice, we stained cervical sections for
MCM7. It was evident that MCM7 expression was up-
regulated in K14E6/K14E7 mice compared with NTG control
mice, and MPA did not alter the staining pattern (Figure 3A).
ERa is required for the continued growth of cervical cancer.15
ERa is also required for expression of PR in the murine cervix
(J. Son, F.F. Mehta, S.H. Chung, unpublished data). We found
that there was no appreciable difference in staining patterns of
ERa or PR in the cervix ofMPA-treatedK14E6/K14E7 double
transgenic mice comparedwith vehicle-treated controls (Figure
3B). These results indicate that MPA has no effect on expres-
sion of HPV oncogenes or ERa.
Ablation of PR Has a Marginal Effect on Neoplasia of
the Female Lower Reproductive Tracts in K14E7
Transgenic Mice
We next sought to determine whether ablation of PR alone
augments disease severity. We generated ovary-intact mice/ Background
Cancer and dysplasia, No. Cancer incidence, %
CIN3 (VIN3) Cervix (vagina) Cervix (vagina)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
6 (0) 2 (2) 15.4 (15.4)
7 (2) 5 (0) 20.8 (0)
ix or, in parentheses, the vagina.
R, progesterone receptor; VIN, vaginal intraepithelial neoplasia.
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Figure 4 Evaluation of the cervical epithelia and cancer in mice treated with E2 for 6 months. A: Photomicrographs of representative H&E-stained cervical
epithelia and cancers in indicated genotypes. Number of mice is indicated in Table 2, and black lines indicate the basement membrane. B: PR-deﬁciency
increases the suprabasal cell proliferation induced by E7. Cervical sections from indicated genotype were stained for BrdU, and nuclei were counterstained with
hematoxylin. Black lines delineate the basement membrane. The suprabasal layer is above the basal layer, the bottom of the epithelia. C: Results shown in B
were quantiﬁed by counting ﬁve random microscopic ﬁelds per mouse. BrdU-positive cells were quantiﬁed in basal and suprabasal layer separately. Results are
shown as means  SEM (nZ 3). PZ 0.02 by Wilcoxon rank sum test. Scale bars: 50 mm (K14E7/PRþ/þ epithelium, A); 100 mm (K14E7/PRþ/þ cancer, A); 20
mm (B). BrdU, bromo-deoxyuridine; E2, estrogen; K14, keratin 14; NTG, non-transgenic; PR, progesterone receptor.
Yoo et alwith four different genotypes (NTG/PRþ/þ, NTG/PR/,
K14E7/PRþ/þ, K14E7/PR/) and treated them for 6
months with E2. The severity of overall cervical disease
state (P Z 2.6  1010) and the cancer incidence (P Z
0.02) were signiﬁcantly increased in K14E7/PRþ/þ mice
compared with NTG/PRþ/þ control mice (Table 2). The
cervical cancer incidence in K14E7/PRþ/þ mice was 20.8%,
which is lower than that on FVB background12 but similar
to that on a mixed genetic background.3,16 Although
cervical cancer was absent, overall cervical disease severity
in NTG/PR/ mice was worse than that in NTG/PRþ/þ
mice (P Z 0.05), consistent with the idea that PR inhibits
cervical neoplasia. Cervical cancer incidence (20.8% versus
15.4%; P Z 0.53) and disease severity (P Z 0.46),
however, were comparable between K14E7/PRþ/þ and
K14E7/PR/ mice (Table 2). The severity of vaginal
disease was comparable between NTG/PRþ/þ and NTG/
PR/ (P Z 0.09) as well as between K14E7/PRþ/þ and
K14E7/PR/ (P Z 0.18). Histopathology of cervical
cancers and epithelia in K14E7/PRþ/þ and K14E7/PR/
mice was indistinguishable (Figure 4A). These results
indicate that the deletion of PR alone has a marginal effect
on the development of cancers in the female lower repro-
ductive tracts of K14E7 mice under the condition used in
this experiment (ie, E2 treatment for 6 months).
Ablation of PR Increases E7-Induced Suprabasal Cell
Proliferation and Squamous Cell Differentiation in the
Female Reproductive Tracts
One of the hallmarks for E7 expression is the increased
suprabasal cell proliferation in the squamous epithelia.3 We
compared cervical epithelial cell proliferation in all four
groups described in Table 2. No signiﬁcant differences were
observed in basal cell proliferation among the study groups,
and suprabasal cell proliferation was signiﬁcantly increased1684in K14E7/PRþ/þ and K14E7/PR/ compared with NTG/
PRþ/þ and NTG/PR/, respectively (Figure 4, B and C).
More importantly, the suprabasal cell proliferation in
K14E7/PR/ mice was signiﬁcantly increased compared
with that in K14E7/PRþ/þ mice (Figure 4C). The cervical
transformation zone within the endocervix is composed of
squamous and columnar epithelial cells, and E7 augments
aberrant squamous differentiation therein.14 Both columnar
and stratiﬁed squamous epithelia were present in the
cervices of NTG/PRþ/þ and K14E7/PRþ/þ mice
(Figure 5A). We noted, however, that squamous cells
occupied the entire cervical epithelia in NTG/PR/ and
K14E7/PR/ mice (Figure 5A). It is also worth noting that
uterine luminal and glandular epithelia of NTG/PR/ and
K14E7/PR/ mice also displayed extensive squamous
differentiation (Figure 5B). No squamous epithelial cells
were observed in the uteri of NTG/PRþ/þ and K14E7/PRþ/þ
mice. These results indicate that PR inhibits E7-mediated
suprabasal cell proliferation as well as squamous epithelial
differentiation in the cervix, which are associated with
cervical cancer.3,14Discussion
E2, P4, and their respective receptors have been well
documented to contribute to the pathogenesis of women’s
cancers, including those of the breast, the ovaries, and the
endometrium.18,31 They have been also suspected to
modulate cervical carcinogenesis in conjunction with
HPV.32 It has been reported that E2 and ERa are required
for the development of cervical cancer in HPV transgenic
mouse models.12,14,16 On the contrary, a role of P4 and PR
in the pathogenesis of cervical disease is poorly understood.
In this study, we provide experimental evidence to suggest
that P4 signaling inhibits cervical carcinogenesis. i) P4ajp.amjpathol.org - The American Journal of Pathology
Figure 5 PR-deﬁciency promotes aberrant
squamous differentiation in the female reproductive
tracts. Representative photomicrographs of H&E-
stained tissue sections from mice indicated in
Table 2 are shown. A: Low-magniﬁcation photomi-
crographs of the endocervix and the lower uterus and
the corresponding high-magniﬁcation photomicro-
graphs of numbered insets. Equivalent endocervical
area in each genotype is enclosed in white boxes.
The right side of each white box is the uterus. Blue
and red arrowheads point to squamous and
columnar epithelia, respectively. Note that the
columnar epithelia are absent in the endocervix and
that the squamous epithelia are present in the uteri
of NTG/PR/ and K14E7/PR/ mice. B: Low-
magniﬁcation photomicrographs of the uteri and
the corresponding high-magniﬁcation photomicro-
graphs of numbered insets. Blue arrowheads indi-
cate the squamous epithelium. Note that the
squamous epithelia are evident in LE and GE of NTG/
PR/ and K14E7/PR/ mice. Scale bars: 500 mm
(K14E7/PRþ/þ, A and B); 100 mm (insets III, A and
B). GE, glandular epithelium; K14, keratin 14; LE,
luminal epithelium; NTG, non-transgenic; PR,
progesterone receptor.
PR Signaling in Cervical Cancerinhibited proliferation of cervical epithelial cells (Figure 1).
ii) A PR agonist MPA promoted regression of cervical
cancer and dysplasia (Table 1 and Supplemental Table S1).
The fact that K14E7/PR/ mice had cervical cancer inci-
dence similar to K14E7/PRþ/þ mice (Table 2) is not
necessarily contradictory to this conclusion. Remember, that
the extent of hormone receptor activation depends on the
concentration of its ligands.33 In other words, low concen-
tration of a ligand activates it weakly, and high concentra-
tion does so more strongly. Ovary-intact mice produce P4 at
a low level when treated with E2.
34 Consistently, mice that
have undergone an ovariectomy and mice with intact
ovaries display similar levels of basal epithelial cell prolif-
eration in the cervix when treated with E2 (S.H. Chung,
unpublished results). E2 treatment regimen used in this
study keeps mice in continuous estrus in which endogenous
P4 levels are low.
11,35 It is conceivable that a weak PR
activation under our cancer study condition (ie, chronic E2
treatment) is not sufﬁcient to suppress cervical carcinogen-
esis but can inhibit aberrant squamous differentiation
(Table 2 and Figure 5).
Abnormal Squamous Differentiation in the Female
Reproductive Tracts of PR/ Mice
The cervix is composed of columnar epithelium and strati-
ﬁed squamous epithelium, which are demarcated at the
squamo-columnar junction in the transformation zone of the
endocervix.11 Although it is poorly understood how the two
different epithelial cell types are maintained at the junction,
an aberrant squamous differentiation called atypical squa-
mous metaplasia is associated with cervical squamousThe American Journal of Pathology - ajp.amjpathol.orgcarcinomas.14,36 We found that PR ablation resulted in the
absence of columnar epithelium in the cervix (Figure 5A). It
also promoted squamous differentiation in the uterus
(normal uteri are devoid of squamous cells) (Figure 5B).
These results indicate that PR is crucial in determining the
fate of epithelial cells in female upper reproductive tracts. In
this regard, it is intriguing that postnatal deletion of
wingless-type MMTV integration site family, member 4
(Wnt4) or ectopic expression of constitutively active
smoothened homolog (Smo) results in squamous differen-
tiation in the uterus.37,38 It will be interesting to determine
whether these genes are involved in the regulation of
squamous differentiation in the cervical transformation zone
and/or cervical carcinogenesis.
Tumor Suppressive Activity of PR in Cervical Cancer
A function of P4 requires PR, which is an ERa target gene in
the female reproductive tract.29 Likewise, function of PR and
ERa depends on their ligands, P4 and E2, respectively.
18,29
During the reproductive cycle in women and mice, an E2
surge is followed by a P4 surge; the former thickens the
epithelium, and the latter wanes it in the female reproductive
tract.35,39 In other words, the ERa signaling promotes
epithelial cell proliferation, and the PR signaling inhibits it in
the same tissues.18We postulate that the P4 surge (ie, maximal
activation of PR) constantly counteracts cervical carcino-
genesis in the context of the menstrual cycle. If this were
correct, the loss of PR expression will be advantageous for
cells to become cancerous. It has been shown that CIN grade
III lesions are more likely to co-express ERa, PR, and Bcl-2
than cervical cancer, suggesting that CIN grade III positive1685
Yoo et alfor these three factors is less likely progress to cervical cancer
in women.40 In addition, loss of heterogeneity at four
microsatellitemarkers, one ofwhich is at the vicinity of thePR
locus, is signiﬁcantly associated with CINs that are prone to
persist or progress.41 Furthermore, it has been observed that
most human cervical cancers do not express PR.42,43 Alter-
natively, persistent estrogenic stimulation (eg, E2-only oral
contraceptives) will inhibit the P4 surge; thus, PR cannot
suppress cervical cancer efﬁciently; perhapsPR loss will have
no beneﬁt to disease progression under such a condition.
Consistently, PR expression was retained in cervical cancers
arising in the HPV transgenic mice treated with E2 for 6
months (Supplemental Figure S1). On the basis of the anti-
cervical cancer effect ofMPA in amousemodel (Table 1) and
the published analyses on PR status in neoplastic disease of
the cervix in women,42,43 we hypothesize that PR functions as
a tumor suppressor in the context of human cervical cancers
such as in endometrial cancer.18Potential PR Target Genes Crucial for Its Tumor
Suppressor Function in the Cervix
P4 is required for regulation of most PR target genes in the
murine uterus.44 Those target genes have been identiﬁed in
mice that underwent an ovariectomy and then treated only
with P4.
44 However, PR is undetectable in the cervix of mice
that underwent an ovariectomy, and E2 treatment induces its
expression in the same tissue (J. Son, F.F. Mehta, and S.H.
Chung, unpublished results).45 In other words, mice that
underwent an ovariectomy need to be treated with E2 plus P4
to identify PR target genes in the cervix. Therefore, it is
unclear which PR target genes identiﬁed in the uterus are
relevant to the disease phenotype in the lower reproductive
tracts. Nonetheless, we note several PR target genes [eg, heart
and neural crest derivatives expressed transcript 2 (Hand2),
mitogen-inducible gene 6 protein homolog (Mig6), myelo-
cytomatosis oncogene (Myc)] that are linked to suppression
of carcinogenesis. A transcription factor Hand2 represses the
expression of stromal ﬁbroblast growth factors that mediate
E2-induced cell proliferation in the uterine epithelia.
46 This
ﬁnding is potentially relevant to our previous results showing
that stromal ERa is required for cervical neoplasia.16 Mig6 is
a tumor suppressor that inhibits epidermal growth factor
receptor-mediated skin cancer and E2-dependent endometrial
cancer.47,48 It is intriguing that ERa is hyperactive in Mig6-
deﬁcient uterine tissues.48 Although it is counterintuitive that
PR activatesMyc, it may be relevant to the tumor suppressive
activity of PR in the lower reproductive tracts. It has been
shown that hyperactivation of Myc promotes terminal
differentiation of keratinocytes in a cyclin E-dependent
manner.49,50 MPA promoted muciniﬁcation of cervical
epithelial cancer cells, which is a terminal differentiation
(Figure 2B). We postulate that up-regulation of Hand2
and/or hyperactivation of Myc contribute, at least in part, to
suppression of cervical cancer by PR.1686In summary, we showed that PR agonist MPA regresses
PR-positive cervical cancers arising in the HPV transgenic
mouse model. Although this may not be applicable to most
patients with cervical cancer (most human cervical cancers
are negative for PR), our results provide a unique model
system to study cross talk between the E2 signaling and the
P4 signaling in the context of a cancer in vivo.
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